DOP2013000072A - ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino. - Google Patents
((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.Info
- Publication number
- DOP2013000072A DOP2013000072A DO2013000072A DO2013000072A DOP2013000072A DO P2013000072 A DOP2013000072 A DO P2013000072A DO 2013000072 A DO2013000072 A DO 2013000072A DO 2013000072 A DO2013000072 A DO 2013000072A DO P2013000072 A DOP2013000072 A DO P2013000072A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- indazol
- vinyl
- dicloropiridin
- etoxi
- pirazol
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 4
- 239000013078 crystal Substances 0.000 title 1
- 229920002554 vinyl polymer Polymers 0.000 title 1
- ORGHESHFQPYLAO-UHFFFAOYSA-N vinyl radical Chemical class C=[CH] ORGHESHFQPYLAO-UHFFFAOYSA-N 0.000 title 1
- -1 4- (2- (5- (1- (3,5-dichloropyridin-4-yl) ethoxy) -1H-indazol-3-yl) vinyl) -1H-pyrazol-1-yl Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a (R)-(E)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1H-indazol-3-il)vinil)-1H-pirazol-1-il)etanol cristalino útil en el tratamiento de cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38991110P | 2010-10-05 | 2010-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2013000072A true DOP2013000072A (es) | 2013-08-15 |
Family
ID=44999860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2013000072A DOP2013000072A (es) | 2010-10-05 | 2013-04-02 | ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8530665B2 (es) |
| EP (1) | EP2625175B1 (es) |
| JP (1) | JP5940547B2 (es) |
| KR (1) | KR101527661B1 (es) |
| CN (1) | CN103153983B (es) |
| AR (1) | AR083091A1 (es) |
| AU (1) | AU2011312485B2 (es) |
| BR (1) | BR112013006336A2 (es) |
| CA (1) | CA2813329C (es) |
| CL (1) | CL2013000884A1 (es) |
| CO (1) | CO6710911A2 (es) |
| DK (1) | DK2625175T3 (es) |
| DO (1) | DOP2013000072A (es) |
| EA (1) | EA021817B1 (es) |
| EC (1) | ECSP13012539A (es) |
| ES (1) | ES2558777T3 (es) |
| HR (1) | HRP20151299T1 (es) |
| HU (1) | HUE026379T2 (es) |
| IL (1) | IL224850A (es) |
| JO (1) | JO3062B1 (es) |
| MA (1) | MA34552B1 (es) |
| ME (1) | ME02307B (es) |
| MX (1) | MX2013003907A (es) |
| NZ (1) | NZ608482A (es) |
| PE (1) | PE20140252A1 (es) |
| PH (1) | PH12013500649A1 (es) |
| PL (1) | PL2625175T3 (es) |
| PT (1) | PT2625175E (es) |
| RS (1) | RS54457B1 (es) |
| SG (1) | SG188286A1 (es) |
| SI (1) | SI2625175T1 (es) |
| TW (1) | TWI418554B (es) |
| UA (1) | UA111725C2 (es) |
| WO (1) | WO2012047699A1 (es) |
| ZA (1) | ZA201301560B (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CN103819396B (zh) * | 2014-02-26 | 2016-06-15 | 四川大学 | 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111705099B (zh) * | 2020-07-01 | 2022-03-08 | 天津药明康德新药开发有限公司 | 一种(s)-1-(3,5-二氯吡啶-4-取代)乙醇的制备方法 |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| JP2023553835A (ja) * | 2020-12-17 | 2023-12-26 | ブロッサムヒル・セラピューティクス・インコーポレイテッド | 大環状化合物およびそれらの使用 |
| MX2023007793A (es) * | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| AU2023282906A1 (en) * | 2022-06-08 | 2024-11-28 | Blossomhill Therapeutics, Inc. | Indazole containing macrocycles and their use |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| BRPI0113757B8 (pt) * | 2000-09-11 | 2017-11-07 | Chiron Corp | derivados de quinolinona como inibidores de tirosina quinase |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| CN1930148A (zh) * | 2004-03-17 | 2007-03-14 | 辉瑞有限公司 | 2 , 5－二甲基－2h－吡唑－3－羧酸{2－氟－5－[3－((e)－2－吡啶－2－基－乙烯基)－1h－吲唑－6－基氨基]－苯基}－酰胺的多晶型物和非晶物 |
| JP4746299B2 (ja) * | 2004-07-16 | 2011-08-10 | ジュズ インターナショナル ピーティーイー エルティーディー | 金属酸化物粉末の製造方法 |
| JP2006163651A (ja) | 2004-12-03 | 2006-06-22 | Sony Computer Entertainment Inc | 表示装置、表示装置の制御方法、プログラム及びフォントデータ |
| US20060160863A1 (en) * | 2005-01-05 | 2006-07-20 | Agouron Pharmaceuticals, Inc. | Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| CN101679356A (zh) * | 2007-04-05 | 2010-03-24 | 辉瑞产品公司 | 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型 |
| JO2860B1 (en) * | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
-
2011
- 2011-09-22 JO JOP/2011/0294A patent/JO3062B1/ar active
- 2011-09-23 AR ARP110103482A patent/AR083091A1/es unknown
- 2011-09-23 TW TW100134428A patent/TWI418554B/zh not_active IP Right Cessation
- 2011-09-29 BR BR112013006336A patent/BR112013006336A2/pt not_active IP Right Cessation
- 2011-09-29 CN CN201180048148.7A patent/CN103153983B/zh not_active Expired - Fee Related
- 2011-09-29 DK DK11771312.3T patent/DK2625175T3/en active
- 2011-09-29 HR HRP20151299TT patent/HRP20151299T1/hr unknown
- 2011-09-29 MX MX2013003907A patent/MX2013003907A/es active IP Right Grant
- 2011-09-29 AU AU2011312485A patent/AU2011312485B2/en not_active Ceased
- 2011-09-29 US US13/248,055 patent/US8530665B2/en not_active Expired - Fee Related
- 2011-09-29 PH PH1/2013/500649A patent/PH12013500649A1/en unknown
- 2011-09-29 WO PCT/US2011/053798 patent/WO2012047699A1/en not_active Ceased
- 2011-09-29 SG SG2013013743A patent/SG188286A1/en unknown
- 2011-09-29 UA UAA201303378A patent/UA111725C2/uk unknown
- 2011-09-29 ME MEP-2015-198A patent/ME02307B/me unknown
- 2011-09-29 MA MA35780A patent/MA34552B1/fr unknown
- 2011-09-29 PE PE2013000789A patent/PE20140252A1/es not_active Application Discontinuation
- 2011-09-29 JP JP2013532838A patent/JP5940547B2/ja not_active Expired - Fee Related
- 2011-09-29 CA CA2813329A patent/CA2813329C/en not_active Expired - Fee Related
- 2011-09-29 KR KR1020137008655A patent/KR101527661B1/ko not_active Expired - Fee Related
- 2011-09-29 PT PT117713123T patent/PT2625175E/pt unknown
- 2011-09-29 PL PL11771312T patent/PL2625175T3/pl unknown
- 2011-09-29 ES ES11771312.3T patent/ES2558777T3/es active Active
- 2011-09-29 EP EP11771312.3A patent/EP2625175B1/en active Active
- 2011-09-29 EA EA201390275A patent/EA021817B1/ru not_active IP Right Cessation
- 2011-09-29 RS RS20150828A patent/RS54457B1/sr unknown
- 2011-09-29 NZ NZ608482A patent/NZ608482A/en not_active IP Right Cessation
- 2011-09-29 SI SI201130673T patent/SI2625175T1/sl unknown
- 2011-09-29 HU HUE11771312A patent/HUE026379T2/en unknown
-
2013
- 2013-02-21 IL IL224850A patent/IL224850A/en not_active IP Right Cessation
- 2013-02-28 ZA ZA2013/01560A patent/ZA201301560B/en unknown
- 2013-04-02 CL CL2013000884A patent/CL2013000884A1/es unknown
- 2013-04-02 DO DO2013000072A patent/DOP2013000072A/es unknown
- 2013-04-03 EC ECSP13012539 patent/ECSP13012539A/es unknown
- 2013-04-08 CO CO13090555A patent/CO6710911A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA111725C2 (uk) | Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол | |
| CO6450624A2 (es) | Compuestos vinil indazolilo | |
| AR089818A1 (es) | Inhibidor de la quinasa que regula la señal de la apoptosis | |
| CU24000B1 (es) | Un derivado 2-carboxamida-cicloamino-urea-tiazol-piridilo | |
| UY34202A (es) | Compuestos fungicidas 2-(2-clor0-4-(4-cloro-fenoxi)-fenil]-1-(1,2,4]triazol-1-1l-etanol alquilo sustituidos | |
| IL210174A0 (en) | 4-(pyridin-4-yl)-1h-(1,3,5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases | |
| UA103625C2 (en) | 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides | |
| MY152114A (en) | Novel pyrazole-4-n-alkoxycarboxamides as microbiocides | |
| TN2015000521A1 (en) | Processes of making and crystalline forms of a mdm2 inhibitor | |
| MY146506A (en) | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor | |
| UA106880C2 (uk) | Нові гербіциди | |
| BR112013029999A2 (pt) | derivados de tiazol | |
| UA102289C2 (ru) | Гербициды, полученные из циклопентадиона | |
| MA31985B1 (fr) | (r)-2-(4-cyclopropanesulfonyl-phényl)-n-pyrazin-2-yl-3-(tétrahydropyran-4-yl)- propionamide cristallin | |
| UA103468C2 (ru) | Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3 | |
| MY159479A (en) | Herbicides | |
| TN2013000142A1 (en) | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor | |
| CY1117146T1 (el) | Κρυσταλλικη (r)-(ε)-2-(4-(2-(5-(1-(3,5-διχλωροπυριδινο-4-υλ)αιθοξυ)-1 η-ινδαζολο-3-υλ)βινυλο)-1 η-πυραζολο-1-υλ)αιθανολη και η χρηση της ως αναστολεα του fgfr | |
| TH132151A (th) | ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก | |
| MY162757A (en) | New Crystalline Forms of 4,4’-[4-Fluoro-7-({4-[4-(3-Fluoro-2-Methylphenyl) Butoxy] Phenyl}Ethynyl)-2-Methyl-1H-Indole-1, 3-Diyl] Dibutanoic Acid | |
| TH115254A (th) | สารประกอบไวนิลอินดาโซลอิล | |
| UA114081U (uk) | 5-(2-(4-(диметиламіно)бензиліден)гідразиніл)-4-феніл-4h-1,2,4-триазол-3-тіолу гідрохлорид, що стимулює ріст пшениці озимої | |
| UA95803C2 (ru) | Замещенные пиридиламидные соединения как модуляторы гистаминового н3-рецептора | |
| HK1155153A (en) | 1, 2 disubstituted heterocyclic compounds | |
| UA88738U (uk) | 5-(гептилтіо)-3-(феноксиметил)-1н-1,2,4-тріазол, що виявляє антигіпоксичну активність |